Neuland Laboratories (524558) Q3 24/25 earnings summary

Executive summary

• Q3 total income rose 1.8% year-over-year to ₹401.9 crore, mainly driven by Prime GDS and Specialty business, with marginal topline growth aligning with FY25 expectations and strategic initiatives.

• Revenues were driven by key molecules in the CMS and GDS segments, with increased customer traction and capacity expansion plans.

• Business momentum is expected to remain strong in the medium and long term, supported by new and existing customer projects and investments in peptide capacity.

• Unaudited financial results for the quarter and nine months ended December 31, 2024, were approved by the Board on February 10, 2025.

• Business remains uneven quarter-to-quarter due to the nature of CDMO and specialty GDS segments; annual evaluation is more accurate.

Financial highlights

• Q3 gross margin was 53.2%, down from 59.8% in Q3 FY24; Q3 EBITDA (excluding exceptional items) was ₹90.3 crore (22.5% margin), down from ₹122.7 crore in Q3 FY24.

• Q3 profit after tax was ₹101.4 crore, including an exceptional gain of ₹55.8 crore from investment property sale; 9MFY25 PAT was ₹231.7 crore, nearly flat YoY (includes ₹76.4 crore exceptional gain).

• Nine-month revenue was ₹1161.5 crore, a 1.7% decline year-over-year.

• Net debt at Q3FY25 end was ₹(185.1) crore, a significant improvement from ₹(44.6) crore at Q3FY24 end.

• Basic and diluted EPS for Q3 FY25 were ₹79.18 (consolidated), significantly higher than previous quarters.

Outlook and guidance

• FY25 is projected to be flat, with growth expected to resume in FY26 as new facilities and commercial molecules scale up.

• Management remains optimistic about sustainable long-term growth, driven by customer acquisition, expertise enhancement, and flexible capacity expansion.

• Recently commercialized molecules are expected to scale, with ongoing investments in peptide manufacturing capacity.

• Ongoing investments in capacity, especially in peptides, are expected to drive long-term growth.

• Management remains cautiously optimistic, citing a robust order pipeline and customer interest.